RCUS — Arcus Biosciences, Inc. stock price, charts and financials

QT77Arcus Biosciences, Inc.

Arcus Biosciences, Inc. (NYSE: RCUS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
28.77
+0.15+0.52%
OverviewShort InterestFilings
RCUSQT77Arcus Biosciences, Inc.·NYSE
28.77+0.52%
News
Up 0.5% — Arcus Biosciences Q2 Earnings Call Highlights (marketbeat.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IDYA-0.86%$36.70RLAY+1.16%$20.00ALMS-0.76%$27.39LEGN-0.53%$20.64TNGX-0.55%$26.92CPRX+0.00%$31.49TLX+2.26%$11.78DNLI-0.72%$24.65
Snapshot
Index-P/E-EPS (ttm)-3.17Insider Own43.95%Shs Outstand125.77MPerf Week1.53%
Market Cap3.60BForward P/E-EPS next Y-3.45Insider Trans-0.20%Shs Float88.98MPerf Month-4.47%
Enterprise Value3.56BPEG0.29EPS next Q-Inst Own-Short Float14.11%Perf Quarter15.50%
Income-450.67MP/S30.77EPS this Y-15.81%Inst Trans-Short Ratio9.53Perf Half Y42.89%
Sales117.00MP/B7.78EPS next Y6.00%ROA-48.92%Short Interest12.56MPerf YTD20.10%
Book/sh-P/C-EPS next 5Y-ROE-87.98%52W High31.91 -9.83%Perf Year201.58%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-65.76%52W Low8.93 222.30%Perf 3Y49.53%
Dividend Est.-EV/EBITDA-Sales past 3/5Y30.16% 25.93%Gross Margin94.02%Volatility4.98% 5.03%Perf 5Y-8.88%
Dividend TTM-EV/Sales30.46EPS Y/Y TTM-0.96%Oper. Margin-415.38%ATR (14)1.54Perf 10Y-
Dividend Ex-Date-Quick Ratio3.82Sales Y/Y TTM-8.53%Profit Margin-386.32%RSI (14)52.86Recom2.17
Dividend Gr. 3/5Y-Current Ratio3.82EPS Q/Q10.53%SMA201.66%Beta0.79Target Price36.71
Payout0.00%Debt/Eq0.25Sales Q/Q-39.29%SMA504.98%Rel Volume0.86Prev Close28.62
Employees601LT Debt/Eq0.16EarningsOct 27SMA20021.43%Avg Volume1.23MPrice28.77
IPO DateMar 14, 2018Option/ShortYes / YesEPS/Sales Surpr.-15.88% -42.34%Net Debt/EBITDA0.09Volume1,061,487Change0.52%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedGoldman SachsBuy$34 → $42
Aug-06-26ReiteratedWedbushOutperform$41 → $43
Jul-20-26ReiteratedHC Wainwright & Co.Buy$32 → $45
May-18-26ReiteratedTruist FinancialBuy$30 → $35
May-11-26ReiteratedMorgan StanleyEqual Weight$20 → $22
Apr-20-26ReiteratedLeerink PartnersOutperform$49 → $47
Feb-12-26DowngradeWells FargoOverweight → Equal Weight$26 → $23
Jan-13-26UpgradeGoldman SachsNeutral → Buy$28
Jan-08-26DowngradeMorgan StanleyOverweight → Equal Weight$35 → $20
Dec-12-25ReiteratedTruist FinancialBuy$39 → $30
Latest News
Aug-08-26
Aug-08-2611:04PM
Arcus Biosciences Q2 Earnings Call Highlightsmarketbeat.com
Aug-06-26
Aug-06-2601:33PM
Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26Benzinga
Aug-05-26
Aug-05-2611:40PM
Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcriptseekingalpha.com
09:36PM
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimateszacks.com
04:05PM
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Updatebusinesswire.com
Jul-29-26
Jul-29-2610:26PM
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firmglobenewswire.com
Jul-27-26
Jul-27-2604:35PM
Arcus Biosciences Announces New Employment Inducement Grantsbusinesswire.com
Jul-24-26
Jul-24-2603:32PM
Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line ExpansionsSeekingAlpha
Jul-23-26
Jul-23-2611:36AM
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Studyzacks.com
Jul-22-26
Jul-22-2604:35PM
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patientsbusinesswire.com
04:30PM
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancerbusinesswire.com
Jul-21-26
Jul-21-2604:05PM
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updatesbusinesswire.com
Jul-20-26
Jul-20-2602:45PM
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?Benzinga
Jul-13-26
Jul-13-2607:09PM
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Runfool.com
Jul-09-26
Jul-09-2604:35PM
Arcus Biosciences Announces New Employment Inducement Grantsbusinesswire.com
Company

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue117247258——————
Cost of Goods Sold Incl. D&A7100——————
Gross Profit110237258——————
Selling, General and Administrative Excl. Other106110120——————
Research and Development497523448——————
Other Operating Expense-7-1020——————
Operating Income-486-386-330——————
Interest Expense2384——————
Unusual Expense
—————————
Non-Operating Income (Expense)574151——————
Net Income Before Taxes-452-353-283——————
Income Taxes001——————
Consolidated Net Income-452-353-283——————
Net Income From Continuing Operations-452-353-284——————
Net Income-452-353-283——————
EPS (Recurring)-3.93-3.29-3.14——————
EPS (Basic, Before Extraordinaries)-3.93-3.29-3.14——————
EPS (Diluted)-3.93-3.29-3.14——————
EBITDA-419-335-269——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio30.9810.325.19——————
Gross Margin94.0295.95100.00——————
Operating Margin-415.38-156.28-127.91——————
Net Margin-386.32-142.91-109.69——————
Shares Outstanding12610790——————
Market Capitalization3,6252,5501,340——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$34.55$27.03$19.51$12.00$4.48● Close Price0.00M1.34M2.67M4.01M5.34MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Jaen Juan C.PresidentJul 10 '26Sale28.6220,067574,288822,240Jul 13
Jaen Juan C.PresidentJul 09 '26Sale30.0548,5021,457,631842,307Jul 13
Jaen Juan C.PresidentJun 24 '26Sale29.666,431190,740890,809Jun 24
Jaen Juan C.PresidentJun 23 '26Sale27.7315,764437,100897,240Jun 24
Jaen Juan C.PresidentJun 22 '26Sale27.039,236249,661913,004Jun 24
Tang Carolyn C.General CounselJun 11 '26Option Exercise2.5734,09087,748184,607Jun 12
Azoy AlexanderChief Accounting OfficerJun 01 '26Sale25.772,56266,02439,581Jun 01
Goeltz II Robert C.Chief Financial OfficerMay 11 '26Sale25.637,763198,96684,161May 12
Jaen Juan C.PresidentJan 05 '26Sale21.4131,823681,342922,240Jan 07
Goeltz II Robert C.Chief Financial OfficerDec 31 '25Sale23.386,552153,18667,924Jan 02
Azoy AlexanderChief Accounting OfficerDec 18 '25Sale22.254,34396,61418,531Dec 18
Azoy AlexanderChief Accounting OfficerDec 17 '25Sale22.162,11346,82322,874Dec 18
Tang Carolyn C.General CounselDec 17 '25Sale22.166,810150,906124,734Dec 18
Markus RichardChief Medical OfficerDec 17 '25Sale22.164,49499,58565,647Dec 18
Goeltz II Robert C.Chief Financial OfficerDec 17 '25Sale22.165,960132,07174,476Dec 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.